Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview

Karyopharm Therapeutics

11/08/2026 14:28

Karyopharm Therapeutics Inc. KPTI.OQ KPTI.O is expected to  show a fall in quarterly revenue when it reports  results on August 13 for the period ending June 30 2026
The Newton Massachusetts-based  company is expected to report a 15.1% decrease in revenue to $32.188 million from $37.93 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Karyopharm Therapeutics Inc. is for a loss of $1.28 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Karyopharm Therapeutics Inc. is $7.00, about 257.1% above its last closing price of $1.96
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-1.46
-1.43
-1.02
Beat
28.6
Dec. 31 2026
-1.87
-1.99
-2.22
Missed
-11.3
Sep. 30 2025
-3.43
-3.13
-3.82
Missed
-22​
Jun. 30 2025
-4.00
-4.10
-4.32
Missed
-5.4
​​Mar. 31 2025
-4.21
-4.18
-2.77
Beat
33.7
Dec. 31 2024
-4.32
-3.92
-3.60
Beat
8.2​
Sep. 30 2024
-3.76
-3.94
-3.90
Beat
1.1
Jun. 30 2024
-4.31
-4.48
2.25
Beat
150.2
This summary was machine generated August 11 at 13:28 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)